EthicsdoctorP Profile Banner
Jeffrey peppercorn MD Profile
Jeffrey peppercorn MD

@EthicsdoctorP

Followers
554
Following
2K
Media
77
Statuses
663

Oncologist and Bioethicist with interest in health policy and rock n roll. Editor-in-Chief JCO Oncology Practice. Tweets and opinions are my own.

Joined October 2016
Don't wanna be here? Send us removal request.
@JCOOP_ASCO
JCO Oncology Practice
9 days
Risk of Colitis in Patients With Inflammatory Bowel Disease or Microscopic Colitis Exposed to Checkpoint Inhibitors: A National Danish Cohort Study. Read the full article.
Tweet card summary image
ascopubs.org
PURPOSEPatients with intestinal inflammatory diseases such as ulcerative colitis (UC), Crohn's disease (CD), and microscopic colitis (MC) are excluded from clinical trials with immune checkpoint...
0
2
0
@ASCO
ASCO
22 days
This #JCOOP simultaneous publication is being presented now during Rapid Oral Abstract Session B at #ASCOQLTY25 ➡️
@JCOOP_ASCO
JCO Oncology Practice
22 days
‼️ #ASCOQLTY25 simultaneous publication by Budhu, et al:  Screened But Still Struggling: Challenges in Delivering Financial Assistance After Positive Financial Toxicity Screens: https://t.co/134bFFIAfP
0
4
15
@anhbl9
Anh Lam (she/her)
22 days
Emily Mackler, PharmD presented her team’s work on cancer drug repositories (CDRs) and found significant participation with YesTx CDR Network leading to patients receiving over $15.5 million in cancer medication at no cost! https://t.co/w2qgSjC0vV #ASCOQLTY25
0
2
9
@JCOOP_ASCO
JCO Oncology Practice
22 days
‼️ #ASCOQLTY25 simultaneous publication by Roberts, et al:  Racial and Ethnic Diversity of the Oncology Workforce: Projections from 2020 to 2060: https://t.co/dSnALMVfEi
0
4
10
@JCOOP_ASCO
JCO Oncology Practice
22 days
‼️ #ASCOQLTY25 simultaneous publication by Mackler, et al:  Transforming Cancer Drug Access: Insights on Utilization and Clinician Satisfaction in a Statewide Cancer Drug Repository Network: https://t.co/kDEBAnsKW6
0
5
11
@JCOOP_ASCO
JCO Oncology Practice
23 days
‼️ #QCS25 simultaneous publication by Henrikson, et al:  Financial Navigation for People Newly Diagnosed With Cancer: Primary Outcomes From the CAFÉ Randomized Trial: https://t.co/oTGMTM9Wvb
0
3
5
@Thalcin
Thierry Alcindor, MD, MSc
2 months
An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last | JCO Oncology Practice
Tweet card summary image
ascopubs.org
0
1
3
@fumikochino
Fumiko Ladd Chino, MD, FASCO
2 months
⏰Discounted access to the 2025 @ASCO Quality Care Symposium is ending soon! Join us at #ASCOQLTY25 the premier meeting addressing quality, safety, & efficiency of cancer care delivery. 📆 Early Registration by: Wed, September 3 at 11:59 PM (ET)     👉 https://t.co/DBPIaAFgP0
1
14
24
@JCOOP_ASCO
JCO Oncology Practice
4 months
Longitudinal Associations Between Financial Toxicity and Health-Related Quality of Life for Patients With Cancer. Read the full article.
Tweet card summary image
ascopubs.org
PURPOSEEvaluate the longitudinal relationship between financial toxicity (FT), health-related quality of life (HR-QOL), and psychological distress for patients with cancer.METHODSAdults with cancer...
0
2
15
@NiuSanford
Dr. Nina Niu Sanford
5 months
Calling all oncology trainees & early career faculty who love to write!✍️ Please consider submitting your work to the first ever Narrative Medicine Contest in @JCO_ASCO. Deadline is 8/31/2025. https://t.co/vy1uGSCWL0
6
33
116
@JCOOP_ASCO
JCO Oncology Practice
5 months
Remote Clinical Pharmacist Impact on Reducing Total Cost of Care in Enhancing Oncology Model–Enrolled Oncology Practices. Read full article.
Tweet card summary image
ascopubs.org
PURPOSEThe Enhancing Oncology Model (EOM) is a voluntary, risk-based payment model implemented by the Centers for Medicare & Medicaid Services (CMS) to improve cancer care while reducing the total...
0
4
8
@RyanNipp
Ryan Nipp, MD, MPH, MBA, FASCO
5 months
Addressing Tumor Board Bad Habits and Risks: A Call for Rational Resource Management. https://t.co/ZIxY5lWjns @ASCO @JCO_ASCO @JCOOP_ASCO #CancerCare #MedEd #MedTwitter @EthicsdoctorP
1
13
30
@VivekSubbiah
Vivek Subbiah, MD
5 months
🚨 Wow! #ASCO25 @ASCO was absolutely massive! 10 @NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert
6
182
588
@EthicsdoctorP
Jeffrey peppercorn MD
5 months
Another great #ASCO25 wonderful to see my amazing JCO Oncology Practice colleagues! 📝 Loved Dr. DeMichele’s discussion of SERENA-6 and the incredible CHALLENGE trial of exercise in colon cancer survivors. 🏃‍♂️ And a chance to hang out for a few hours with my daughter! 🥰
0
0
12
@QasimHussainiMD
Qasim Hussaini, MD
5 months
Our oral presentation at #ASCO2025 today: environmental burden isn’t just a health hazard - it’s a cancer risk. Counties with higher pollution burden see more cancer, especially lung cancer. Calls for policy action to address environmental justice. @ONealCancerUAB @azar_mak
0
4
12
@TheDrWood
Shearwood McClelland III, M.D.
5 months
It continues to be a great honor to serve on the @JCOOP_ASCO Editorial Board; very proud of the @DrMcClellandLab’s 2024 proton #RadOnc paper ➡️ most downloaded editorial in 2024! Always open for submission, 20 years strong! https://t.co/ovDJFnhv60 #ASCO25 #RepresentationMatters
0
2
10
@jamecancerdoc
Jame Abraham, MD, FACP
5 months
Thank you and congratulations to ⁦@SagarLonialMD⁩ and ⁦@AparGanti⁩ - The amazing Associate Editors of ⁦@JCOOP_ASCO⁩ now rotating off their responsibilities! It was a privilege to work with them for the past 6 years ! ⁦@EthicsdoctorP⁩ !
1
6
21
@DrHBurstein
Harold J. Burstein, MD, PhD, FASCO
5 months
Thematic take on @ASCO breast cancer abstracts: 1. Move 'em up. DB09, ASCENT-04, SERENA-6 are really just trials of using agents earlier in the course of advanced disease. Since all patients with the right tumor subtype will eventually get the agent, the only real question is:
1
28
81
@jamecancerdoc
Jame Abraham, MD, FACP
7 months
Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring | @JCOOP_ASCO #JCOOP @OncoAlert https://t.co/c70Ze5BEVm
1
21
61